Skip to main content
Top
Published in: Pediatric Rheumatology 1/2010

Open Access 01-12-2010 | Research

Nonsteroidal Anti-Inflammatory Drugs: A survey of practices and concerns of pediatric medical and surgical specialists and a summary of available safety data

Authors: Deborah M Levy, Lisa F Imundo

Published in: Pediatric Rheumatology | Issue 1/2010

Login to get access

Abstract

Objectives

To examine the prescribing habits of NSAIDs among pediatric medical and surgical practitioners, and to examine concerns and barriers to their use.

Methods

A sample of 1289 pediatricians, pediatric rheumatologists, sports medicine physicians, pediatric surgeons and pediatric orthopedic surgeons in the United States and Canada were sent an email link to a 22-question web-based survey.

Results

338 surveys (28%) were completed, 84 were undeliverable. Of all respondents, 164 (50%) had never prescribed a selective cyclooxygenase-2 (COX-2) NSAID. The most common reasons for ever prescribing an NSAID were musculoskeletal pain, soft-tissue injury, fever, arthritis, fracture, and headache. Compared to traditional NSAIDs, selective COX-2 NSAIDs were believed to be as safe (42%) or safer (24%); have equal (52%) to greater efficacy (20%) for pain; have equal (59%) to greater efficacy (15%) for inflammation; and have equal (39%) to improved (44%) tolerability. Pediatric rheumatologists reported significantly more frequent abdominal pain (81% vs. 23%), epistaxis (13% vs. 2%), easy bruising (64% vs. 8%), headaches (21% vs. 1%) and fatigue (12% vs. 1%) for traditional NSAIDs than for selective COX-2 NSAIDs. Prescribing habits of NSAIDs have changed since the voluntary withdrawal of rofecoxib and valdecoxib; 3% of pediatric rheumatologists reported giving fewer traditional NSAID prescriptions, and while 57% reported giving fewer selective COX-2 NSAIDs, 26% reported that they no longer prescribed these medications.

Conclusions

Traditional and selective COX-2 NSAIDs were perceived as safe by pediatric specialists. The data were compared to the published pediatric safety literature.
Appendix
Available only for authorised users
Literature
1.
go back to reference Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR: Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA. 1999, 96 (13): 7563-8. 10.1073/pnas.96.13.7563.PubMedCentralCrossRefPubMed Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR: Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA. 1999, 96 (13): 7563-8. 10.1073/pnas.96.13.7563.PubMedCentralCrossRefPubMed
2.
go back to reference Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000, 284 (10): 1247-55. 10.1001/jama.284.10.1247.CrossRefPubMed Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000, 284 (10): 1247-55. 10.1001/jama.284.10.1247.CrossRefPubMed
3.
go back to reference Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000, 343 (21): 1520-8. 10.1056/NEJM200011233432103.CrossRefPubMed Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000, 343 (21): 1520-8. 10.1056/NEJM200011233432103.CrossRefPubMed
4.
go back to reference Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M: Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005, 352 (11): 1071-80. 10.1056/NEJMoa050405.CrossRefPubMed Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M: Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005, 352 (11): 1071-80. 10.1056/NEJMoa050405.CrossRefPubMed
5.
go back to reference Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, Boyce SW, Verburg KM: Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 2005, 352 (11): 1081-91. 10.1056/NEJMoa050330.CrossRefPubMed Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, Boyce SW, Verburg KM: Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 2005, 352 (11): 1081-91. 10.1056/NEJMoa050330.CrossRefPubMed
6.
go back to reference Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA: Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005, 352 (11): 1092-102. 10.1056/NEJMoa050493.CrossRefPubMed Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA: Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005, 352 (11): 1092-102. 10.1056/NEJMoa050493.CrossRefPubMed
7.
go back to reference Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C: Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006, 332 (7553): 1302-8. 10.1136/bmj.332.7553.1302.PubMedCentralCrossRefPubMed Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C: Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006, 332 (7553): 1302-8. 10.1136/bmj.332.7553.1302.PubMedCentralCrossRefPubMed
8.
go back to reference McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA: Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA. 1999, 96 (1): 272-7. 10.1073/pnas.96.1.272.PubMedCentralCrossRefPubMed McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA: Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA. 1999, 96 (1): 272-7. 10.1073/pnas.96.1.272.PubMedCentralCrossRefPubMed
9.
go back to reference Keenan GF, Giannini EH, Athreya BH: Clinically significant gastropathy associated with nonsteroidal antiinflammatory drug use in children with juvenile rheumatoid arthritis. J Rheumatol. 1995, 22 (6): 1149-51.PubMed Keenan GF, Giannini EH, Athreya BH: Clinically significant gastropathy associated with nonsteroidal antiinflammatory drug use in children with juvenile rheumatoid arthritis. J Rheumatol. 1995, 22 (6): 1149-51.PubMed
10.
go back to reference Berezin SH, Bostwick HE, Halata MS, Feerick J, Newman LJ, Medow MS: Gastrointestinal bleeding in children following ingestion of low-dose ibuprofen. Journal of pediatric gastroenterology and nutrition. 2007, 44 (4): 506-8. 10.1097/MPG.0b013e31802d4add.CrossRefPubMed Berezin SH, Bostwick HE, Halata MS, Feerick J, Newman LJ, Medow MS: Gastrointestinal bleeding in children following ingestion of low-dose ibuprofen. Journal of pediatric gastroenterology and nutrition. 2007, 44 (4): 506-8. 10.1097/MPG.0b013e31802d4add.CrossRefPubMed
11.
go back to reference Barron KS, Person DA, Brewer EJ: The toxicity of nonsteroidal antiinflammatory drugs in juvenile rheumatoid arthritis. J Rheumatol. 1982, 9 (1): 149-55.PubMed Barron KS, Person DA, Brewer EJ: The toxicity of nonsteroidal antiinflammatory drugs in juvenile rheumatoid arthritis. J Rheumatol. 1982, 9 (1): 149-55.PubMed
12.
go back to reference Mulberg AE, Linz C, Bern E, Tucker L, Verhave M, Grand RJ: Identification of nonsteroidal antiinflammatory drug-induced gastroduodenal injury in children with juvenile rheumatoid arthritis. J Pediatr. 1993, 122 (4): 647-9. 10.1016/S0022-3476(05)83556-5.CrossRefPubMed Mulberg AE, Linz C, Bern E, Tucker L, Verhave M, Grand RJ: Identification of nonsteroidal antiinflammatory drug-induced gastroduodenal injury in children with juvenile rheumatoid arthritis. J Pediatr. 1993, 122 (4): 647-9. 10.1016/S0022-3476(05)83556-5.CrossRefPubMed
13.
go back to reference Gazarian M, Berkovitch M, Koren G, Silverman ED, Laxer RM: Experience with misoprostol therapy for NSAID gastropathy in children. Ann Rheum Dis. 1995, 54 (4): 277-80. 10.1136/ard.54.4.277.PubMedCentralCrossRefPubMed Gazarian M, Berkovitch M, Koren G, Silverman ED, Laxer RM: Experience with misoprostol therapy for NSAID gastropathy in children. Ann Rheum Dis. 1995, 54 (4): 277-80. 10.1136/ard.54.4.277.PubMedCentralCrossRefPubMed
14.
go back to reference Hermaszewski R, Hayllar J, Woo P: Gastro-duodenal damage due to non-steroidal anti-inflammatory drugs in children. Br J Rheumatol. 1993, 32 (1): 69-72. 10.1093/rheumatology/32.1.69.CrossRefPubMed Hermaszewski R, Hayllar J, Woo P: Gastro-duodenal damage due to non-steroidal anti-inflammatory drugs in children. Br J Rheumatol. 1993, 32 (1): 69-72. 10.1093/rheumatology/32.1.69.CrossRefPubMed
15.
go back to reference Fahey SM, Silver RM: Use of NSAIDs and COX-2 inhibitors in children with musculoskeletal disorders. J Pediatr Orthop. 2003, 23 (6): 794-9.CrossRefPubMed Fahey SM, Silver RM: Use of NSAIDs and COX-2 inhibitors in children with musculoskeletal disorders. J Pediatr Orthop. 2003, 23 (6): 794-9.CrossRefPubMed
16.
go back to reference Joshi W, Connelly NR, Reuben SS, Wolckenhaar M, Thakkar N: An evaluation of the safety and efficacy of administering rofecoxib for postoperative pain management. Anesth Analg. 2003, 97 (1): 35-8. 10.1213/01.ANE.0000069507.93582.6E.CrossRefPubMed Joshi W, Connelly NR, Reuben SS, Wolckenhaar M, Thakkar N: An evaluation of the safety and efficacy of administering rofecoxib for postoperative pain management. Anesth Analg. 2003, 97 (1): 35-8. 10.1213/01.ANE.0000069507.93582.6E.CrossRefPubMed
17.
go back to reference Sheeran PW, Rose JB, Fazi LM, Chiavacci R, McCormick L: Rofecoxib administration to paediatric patients undergoing adenotonsillectomy. Paediatr Anaesth. 2004, 14 (7): 579-83. 10.1111/j.1460-9592.2004.01263.x.CrossRefPubMed Sheeran PW, Rose JB, Fazi LM, Chiavacci R, McCormick L: Rofecoxib administration to paediatric patients undergoing adenotonsillectomy. Paediatr Anaesth. 2004, 14 (7): 579-83. 10.1111/j.1460-9592.2004.01263.x.CrossRefPubMed
18.
go back to reference Foeldvari I, Szer IS, Zemel LS, Liu-Dumaw M, Bloom BJ: Report of a 12-Week Study of Celecoxib vs. Naproxen in Children with Juvenile Rheumatoid Arthritis. Arthritis Rheum. 2006, 54 (9 suppl): S684- Foeldvari I, Szer IS, Zemel LS, Liu-Dumaw M, Bloom BJ: Report of a 12-Week Study of Celecoxib vs. Naproxen in Children with Juvenile Rheumatoid Arthritis. Arthritis Rheum. 2006, 54 (9 suppl): S684-
19.
go back to reference Reiff A, Lovell DJ, Adelsberg JV, Kiss MH, Goodman S, Zavaler MF, Chen PY, Bolognese JA, Cavanaugh P, Reicin AS, Giannini EH: Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: a 12-week randomized controlled clinical trial with a 52-week open-label extension. J Rheumatol. 2006, 33 (5): 985-95.PubMed Reiff A, Lovell DJ, Adelsberg JV, Kiss MH, Goodman S, Zavaler MF, Chen PY, Bolognese JA, Cavanaugh P, Reicin AS, Giannini EH: Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: a 12-week randomized controlled clinical trial with a 52-week open-label extension. J Rheumatol. 2006, 33 (5): 985-95.PubMed
20.
go back to reference Rattray B, Nugent DJ, Young G: Rofecoxib as adjunctive therapy for haemophilic arthropathy. Haemophilia. 2005, 11 (3): 240-4. 10.1111/j.1365-2516.2005.01087.x.CrossRefPubMed Rattray B, Nugent DJ, Young G: Rofecoxib as adjunctive therapy for haemophilic arthropathy. Haemophilia. 2005, 11 (3): 240-4. 10.1111/j.1365-2516.2005.01087.x.CrossRefPubMed
21.
go back to reference Rattray B, Nugent DJ, Young G: Celecoxib in the treatment of haemophilic synovitis, target joints, andpain in adults and children with haemophilia. Haemophilia. 2006, 12 (5): 514-7. 10.1111/j.1365-2516.2006.01311.x.CrossRefPubMed Rattray B, Nugent DJ, Young G: Celecoxib in the treatment of haemophilic synovitis, target joints, andpain in adults and children with haemophilia. Haemophilia. 2006, 12 (5): 514-7. 10.1111/j.1365-2516.2006.01311.x.CrossRefPubMed
22.
go back to reference Tsoukas C, Eyster ME, Shingo S, Mukhopadhyay S, Giallella KM, Curtis SP, Reicin AS, Melian A: Evaluation of the efficacy and safety of etoricoxib in the treatment of hemophilic arthropathy. Blood. 2006, 107 (5): 1785-90. 10.1182/blood-2004-09-3501.PubMedCentralCrossRefPubMed Tsoukas C, Eyster ME, Shingo S, Mukhopadhyay S, Giallella KM, Curtis SP, Reicin AS, Melian A: Evaluation of the efficacy and safety of etoricoxib in the treatment of hemophilic arthropathy. Blood. 2006, 107 (5): 1785-90. 10.1182/blood-2004-09-3501.PubMedCentralCrossRefPubMed
23.
go back to reference Kaplan FS, Shore ES, Glaser DL: The medical management of fibrodysplasia ossificans progressiva: current treatment considerations. Clin Proc Intl Clin Consort FOP. 2005, 1: 1-71. Kaplan FS, Shore ES, Glaser DL: The medical management of fibrodysplasia ossificans progressiva: current treatment considerations. Clin Proc Intl Clin Consort FOP. 2005, 1: 1-71.
24.
go back to reference Bodey B, Siegel SE, Kaiser HE: Cyclooxygenase-2 (COX-2) overexpression in childhood brain tumors. In vivo (Athens Greece). 2006, 20 (4): 519-25. Bodey B, Siegel SE, Kaiser HE: Cyclooxygenase-2 (COX-2) overexpression in childhood brain tumors. In vivo (Athens Greece). 2006, 20 (4): 519-25.
25.
go back to reference Stempak D, Gammon J, Klein J, Koren G, Baruchel S: Single-dose and steady-state pharmacokinetics of celecoxib in children. Clin Pharmacol Ther. 2002, 72 (5): 490-7. 10.1067/mcp.2002.129322.CrossRefPubMed Stempak D, Gammon J, Klein J, Koren G, Baruchel S: Single-dose and steady-state pharmacokinetics of celecoxib in children. Clin Pharmacol Ther. 2002, 72 (5): 490-7. 10.1067/mcp.2002.129322.CrossRefPubMed
26.
go back to reference Boni JP, Korth-Bradley JM, Martin P, Simcoe DK, Richards LS, Rennebohm R, Walson PD: Pharmacokinetics of etodolac in patients with stable juvenile rheumatoid arthritis. Clin Ther. 1999, 21 (10): 1715-24. 10.1016/S0149-2918(99)80050-2.CrossRefPubMed Boni JP, Korth-Bradley JM, Martin P, Simcoe DK, Richards LS, Rennebohm R, Walson PD: Pharmacokinetics of etodolac in patients with stable juvenile rheumatoid arthritis. Clin Ther. 1999, 21 (10): 1715-24. 10.1016/S0149-2918(99)80050-2.CrossRefPubMed
27.
go back to reference Dix P, Prosser DP, Streete P: A pharmacokinetic study of piroxicam in children. Anaesthesia. 2004, 59 (10): 984-7. 10.1111/j.1365-2044.2004.03806.x.CrossRefPubMed Dix P, Prosser DP, Streete P: A pharmacokinetic study of piroxicam in children. Anaesthesia. 2004, 59 (10): 984-7. 10.1111/j.1365-2044.2004.03806.x.CrossRefPubMed
28.
go back to reference Cummings SM, Savitz LA, Konrad TR: Reported response rates to mailed physician questionnaires. Health services research. 2001, 35 (6): 1347-55.PubMedCentralPubMed Cummings SM, Savitz LA, Konrad TR: Reported response rates to mailed physician questionnaires. Health services research. 2001, 35 (6): 1347-55.PubMedCentralPubMed
29.
go back to reference Leece P, Bhandari M, Sprague S, Swiontkowski MF, Schemitsch EH, Tornetta P, Devereaux PJ, Guyatt GH: Internet versus mailed questionnaires: a controlled comparison (2). Journal of medical Internet research. 2004, 6 (4): e39-10.2196/jmir.6.4.e39.PubMedCentralCrossRefPubMed Leece P, Bhandari M, Sprague S, Swiontkowski MF, Schemitsch EH, Tornetta P, Devereaux PJ, Guyatt GH: Internet versus mailed questionnaires: a controlled comparison (2). Journal of medical Internet research. 2004, 6 (4): e39-10.2196/jmir.6.4.e39.PubMedCentralCrossRefPubMed
30.
go back to reference McMahon SR, Iwamoto M, Massoudi MS, Yusuf HR, Stevenson JM, David F, Chu SY, Pickering LK: Comparison of e-mail fax and postal surveys of pediatricians. Pediatrics. 2003, 111 (4 Pt 1): e299-303. 10.1542/peds.111.4.e299.CrossRefPubMed McMahon SR, Iwamoto M, Massoudi MS, Yusuf HR, Stevenson JM, David F, Chu SY, Pickering LK: Comparison of e-mail fax and postal surveys of pediatricians. Pediatrics. 2003, 111 (4 Pt 1): e299-303. 10.1542/peds.111.4.e299.CrossRefPubMed
31.
go back to reference VanGeest JB, Johnson TP, Welch VL: Methodologies for improving response rates in surveys of physicians: a systematic review. Eval Health Prof. 2007, 30 (4): 303-21. 10.1177/0163278707307899.CrossRefPubMed VanGeest JB, Johnson TP, Welch VL: Methodologies for improving response rates in surveys of physicians: a systematic review. Eval Health Prof. 2007, 30 (4): 303-21. 10.1177/0163278707307899.CrossRefPubMed
32.
go back to reference MacPherson I, Bisset A: Not another questionnaire!: eliciting the views of general practitioners. Fam Pract. 1995, 12 (3): 335-8. 10.1093/fampra/12.3.335.CrossRefPubMed MacPherson I, Bisset A: Not another questionnaire!: eliciting the views of general practitioners. Fam Pract. 1995, 12 (3): 335-8. 10.1093/fampra/12.3.335.CrossRefPubMed
33.
go back to reference Kaner EF, Haighton CA, McAvoy BR: 'So much post so busy with practice--so no time!': a telephone survey of general practitioners' reasons for not participating in postal questionnaire surveys. Br J Gen Pract. 1998, 48 (428): 1067-9.PubMedCentralPubMed Kaner EF, Haighton CA, McAvoy BR: 'So much post so busy with practice--so no time!': a telephone survey of general practitioners' reasons for not participating in postal questionnaire surveys. Br J Gen Pract. 1998, 48 (428): 1067-9.PubMedCentralPubMed
34.
go back to reference Field TS, Cadoret CA, Brown ML, Ford M, Greene SM, Hill D, Hornbrook MC, Meenan RT, White MJ, Zapka JM: Surveying physicians: do components of the "Total Design Approach" to optimizing survey response rates apply to physicians?. Med Care. 2002, 40 (7): 596-605. 10.1097/00005650-200207000-00006.CrossRefPubMed Field TS, Cadoret CA, Brown ML, Ford M, Greene SM, Hill D, Hornbrook MC, Meenan RT, White MJ, Zapka JM: Surveying physicians: do components of the "Total Design Approach" to optimizing survey response rates apply to physicians?. Med Care. 2002, 40 (7): 596-605. 10.1097/00005650-200207000-00006.CrossRefPubMed
35.
go back to reference Lesko SM, Mitchell AA: An assessment of the safety of pediatric ibuprofen. A practitioner-based randomized clinical trial. Jama. 1995, 273 (12): 929-33. 10.1001/jama.273.12.929.CrossRefPubMed Lesko SM, Mitchell AA: An assessment of the safety of pediatric ibuprofen. A practitioner-based randomized clinical trial. Jama. 1995, 273 (12): 929-33. 10.1001/jama.273.12.929.CrossRefPubMed
36.
go back to reference Giannini EH, Brewer EJ, Miller ML, Gibbas D, Passo MH, Hoyeraal HM: Ibuprofen suspension in the treatment of juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. J Pediatr. 1990, 117 (4): 645-52. 10.1016/S0022-3476(05)80708-5.CrossRefPubMed Giannini EH, Brewer EJ, Miller ML, Gibbas D, Passo MH, Hoyeraal HM: Ibuprofen suspension in the treatment of juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. J Pediatr. 1990, 117 (4): 645-52. 10.1016/S0022-3476(05)80708-5.CrossRefPubMed
37.
go back to reference Shah SS, Ohlsson A: Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev. 2006, CD004213-1 Shah SS, Ohlsson A: Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev. 2006, CD004213-1
38.
go back to reference Moffett BS, Wann TI, Carberry KE, Mott AR: Safety of ketorolac in neonates and infants after cardiac surgery. Paediatr Anaesth. 2006, 16 (4): 424-8. 10.1111/j.1460-9592.2005.01806.x.CrossRefPubMed Moffett BS, Wann TI, Carberry KE, Mott AR: Safety of ketorolac in neonates and infants after cardiac surgery. Paediatr Anaesth. 2006, 16 (4): 424-8. 10.1111/j.1460-9592.2005.01806.x.CrossRefPubMed
39.
go back to reference Gupta A, Daggett C, Ludwick J, Wells W, Lewis A: Ketorolac after congenital heart surgery: does it increase the risk of significant bleeding complications?. Paediatr Anaesth. 2005, 15 (2): 139-42. 10.1111/j.1460-9592.2005.01409.x.CrossRefPubMed Gupta A, Daggett C, Ludwick J, Wells W, Lewis A: Ketorolac after congenital heart surgery: does it increase the risk of significant bleeding complications?. Paediatr Anaesth. 2005, 15 (2): 139-42. 10.1111/j.1460-9592.2005.01409.x.CrossRefPubMed
40.
go back to reference Gupta A, Daggett C, Drant S, Rivero N, Lewis A: Prospective randomized trial of ketorolac after congenital heart surgery. Journal of cardiothoracic and vascular anesthesia. 2004, 18 (4): 454-7. 10.1053/j.jvca.2004.05.024.CrossRefPubMed Gupta A, Daggett C, Drant S, Rivero N, Lewis A: Prospective randomized trial of ketorolac after congenital heart surgery. Journal of cardiothoracic and vascular anesthesia. 2004, 18 (4): 454-7. 10.1053/j.jvca.2004.05.024.CrossRefPubMed
41.
go back to reference Romsing J, Ostergaard D, Walther-Larsen S, Valentin N: Analgesic efficacy and safety of preoperative versus postoperative ketorolac in paediatric tonsillectomy. Acta Anaesthesiol Scand. 1998, 42 (7): 770-5. 10.1111/j.1399-6576.1998.tb05320.x.CrossRefPubMed Romsing J, Ostergaard D, Walther-Larsen S, Valentin N: Analgesic efficacy and safety of preoperative versus postoperative ketorolac in paediatric tonsillectomy. Acta Anaesthesiol Scand. 1998, 42 (7): 770-5. 10.1111/j.1399-6576.1998.tb05320.x.CrossRefPubMed
42.
go back to reference Chauhan RD, Idom CB, Noe HN: Safety of ketorolac in the pediatric population after ureteroneocystostomy. J Urol. 2001, 166 (5): 1873-5. 10.1016/S0022-5347(05)65710-2.CrossRefPubMed Chauhan RD, Idom CB, Noe HN: Safety of ketorolac in the pediatric population after ureteroneocystostomy. J Urol. 2001, 166 (5): 1873-5. 10.1016/S0022-5347(05)65710-2.CrossRefPubMed
43.
go back to reference Lieh-Lai MW, Kauffman RE, Uy HG, Danjin M, Simpson PM: A randomized comparison of ketorolac tromethamine and morphine for postoperative analgesia in critically ill children. Critical care medicine. 1999, 27 (12): 2786-91. 10.1097/00003246-199912000-00030.CrossRefPubMed Lieh-Lai MW, Kauffman RE, Uy HG, Danjin M, Simpson PM: A randomized comparison of ketorolac tromethamine and morphine for postoperative analgesia in critically ill children. Critical care medicine. 1999, 27 (12): 2786-91. 10.1097/00003246-199912000-00030.CrossRefPubMed
44.
go back to reference Buck ML: Clinical experience with ketorolac in children. Ann Pharmacother. 1994, 28 (9): 1009-13.PubMed Buck ML: Clinical experience with ketorolac in children. Ann Pharmacother. 1994, 28 (9): 1009-13.PubMed
45.
go back to reference Ruperto N, Nikishina I, Pachanov ED, Shachbazian Y, Prieur AM, Mouy R, Joos R, Zulian F, Schwarz R, Artamonova V, Emminger W, Bandeira M, Buoncompagni A, Foeldvari I, Falcini F, Baildam E, Kone-Paut I, Alessio M, Gerloni V, Lenhardt A, Martini A, Hanft G, Sigmund R, Simianer S, Pediatric Rheumatology International Trials Organization: A randomized double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: short- and long-term efficacy and safety results. Arthritis Rheum. 2005, 52 (2): 563-72. 10.1002/art.20860.CrossRefPubMed Ruperto N, Nikishina I, Pachanov ED, Shachbazian Y, Prieur AM, Mouy R, Joos R, Zulian F, Schwarz R, Artamonova V, Emminger W, Bandeira M, Buoncompagni A, Foeldvari I, Falcini F, Baildam E, Kone-Paut I, Alessio M, Gerloni V, Lenhardt A, Martini A, Hanft G, Sigmund R, Simianer S, Pediatric Rheumatology International Trials Organization: A randomized double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: short- and long-term efficacy and safety results. Arthritis Rheum. 2005, 52 (2): 563-72. 10.1002/art.20860.CrossRefPubMed
46.
go back to reference Foeldvari I, Burgos-Vargas R, Thon A, Tuerck D: High response rate in the phase I/II study of meloxicam in juvenile rheumatoid arthritis. J Rheumatol. 2002, 29 (5): 1079-83.PubMed Foeldvari I, Burgos-Vargas R, Thon A, Tuerck D: High response rate in the phase I/II study of meloxicam in juvenile rheumatoid arthritis. J Rheumatol. 2002, 29 (5): 1079-83.PubMed
47.
go back to reference Becker-Cohen R, Frishberg Y: Severe reversible renal failure due to naproxen-associated acute interstitial nephritis. European journal of pediatrics. 2001, 160 (5): 293-5. 10.1007/s004310100729.CrossRefPubMed Becker-Cohen R, Frishberg Y: Severe reversible renal failure due to naproxen-associated acute interstitial nephritis. European journal of pediatrics. 2001, 160 (5): 293-5. 10.1007/s004310100729.CrossRefPubMed
48.
go back to reference Laxer RM, Silverman ED, Balfe JW, Poucell S, Baumal R: Naproxen-associated renal failure in a child with arthritis and inflammatory bowel disease. Pediatrics. 1987, 80 (6): 904-8.PubMed Laxer RM, Silverman ED, Balfe JW, Poucell S, Baumal R: Naproxen-associated renal failure in a child with arthritis and inflammatory bowel disease. Pediatrics. 1987, 80 (6): 904-8.PubMed
49.
go back to reference Ray PE, Rigolizzo D, Wara DR, Piel CF: Naproxen nephrotoxicity in a 2-year-old child. American journal of diseases of children (1960). 1988, 142 (5): 524-5.CrossRef Ray PE, Rigolizzo D, Wara DR, Piel CF: Naproxen nephrotoxicity in a 2-year-old child. American journal of diseases of children (1960). 1988, 142 (5): 524-5.CrossRef
50.
go back to reference Schaller S, Kaplan BS: Acute nonoliguric renal failure in children associated with nonsteroidal antiinflammatory agents. Pediatr Emerg Care. 1998, 14 (6): 416-8. 10.1097/00006565-199812000-00011.CrossRefPubMed Schaller S, Kaplan BS: Acute nonoliguric renal failure in children associated with nonsteroidal antiinflammatory agents. Pediatr Emerg Care. 1998, 14 (6): 416-8. 10.1097/00006565-199812000-00011.CrossRefPubMed
51.
go back to reference Fletcher JT, Graf N, Scarman A, Saleh H, Alexander SI: Nephrotoxicity with cyclooxygenase 2 inhibitor use in children. Pediatr Nephrol. 2006, 21 (12): 1893-7. 10.1007/s00467-006-0252-x.CrossRefPubMed Fletcher JT, Graf N, Scarman A, Saleh H, Alexander SI: Nephrotoxicity with cyclooxygenase 2 inhibitor use in children. Pediatr Nephrol. 2006, 21 (12): 1893-7. 10.1007/s00467-006-0252-x.CrossRefPubMed
52.
go back to reference Len C, Hilario MO, Kawakami E, Terreri MT, Becker DJ, Goldenberg J, Fagundes Neto U: Gastroduodenal lesions in children with juvenile rheumatoid arthritis. Hepatogastroenterology. 1999, 46 (26): 991-6.PubMed Len C, Hilario MO, Kawakami E, Terreri MT, Becker DJ, Goldenberg J, Fagundes Neto U: Gastroduodenal lesions in children with juvenile rheumatoid arthritis. Hepatogastroenterology. 1999, 46 (26): 991-6.PubMed
Metadata
Title
Nonsteroidal Anti-Inflammatory Drugs: A survey of practices and concerns of pediatric medical and surgical specialists and a summary of available safety data
Authors
Deborah M Levy
Lisa F Imundo
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Pediatric Rheumatology / Issue 1/2010
Electronic ISSN: 1546-0096
DOI
https://doi.org/10.1186/1546-0096-8-7

Other articles of this Issue 1/2010

Pediatric Rheumatology 1/2010 Go to the issue